USTR Says Stance On Drug Patents 'Flexible' In TPP Talks

Law360, New York (November 27, 2013, 3:17 PM EST) -- The U.S. Trade Representative's office said Wednesday it will seek a “flexible” approach to pharmaceutical intellectual property provisions in the Trans-Pacific Partnership, attempting to allow access to lifesaving medicine while also retaining incentives for new drugs to be developed.

In a blog post, the USTR's office provided details on its negotiating approach across several of the intellectual property provisions that are likely to be included in the TPP, a proposed trade agreement between the U.S. and 11 other Pacific Rim countries. The office said, in general,...
To view the full article, register now.